University of Pittsburgh Cancer Institute (UPCI)

CCSG Acknowledgement

Required CCSG Acknowledgement

The NCI requires that publications acknowledge the UPCI CCSG support, and they are tracking compliance. If a UPCI CCSG-supported Shared Resource provided data used in your publication, please include the following statement in the acknowledgment section of your publication(s):

"This project used the UPCI [insert name(s) of shared resource(s)] that [is/are] supported in part by award P30CA047904."

Shared Resource Directors: Please make sure to include this statement on all of your order forms, contracts, etc. as a reminder to your users to acknowledge the UPCI CCSG support.


Overview

The UPCI Immunologic Monitoring and Cellular Products Laboratory (IMCPL) is responsible for therapeutic cell product generation (CPL), serial monitoring of immunologic functions (IML) in patients with cancer who are treated with biologic therapies, and banking of blood and tissues for patients on clinical protocols (TPF). The IMCPL plays a critical role in supporting novel investigator-initiated immunotherapy trials at UPCI.

Cellular Products Immune Monitoring Tissue Procurement